Home / Articles posted by Peter Göttel

Author: Peter Göttel

NEWS: Berlin Cures’ Steering Committee is Assembled to Facilitate the Design and Implementation of Phase 2 Study of BC 007

ZUG, Switzerland, Dec. 6, 2018 /PRNewswire/ -- Swiss drug developer Berlin Cures Holding AG today announced the establishment of a steering committee of renowned cardiologists focused on ensuring expert input during the design and implementation of the Phase 2 study of BC 007 for the treatment of dilated cardiomyopathy. "By convening an international team of experts to provide guidance around t...
Read More

NEWS: Berlin Cures Announces Successful Completion of Phase 1 Study of BC 007 for the Treatment of Cardiomyopathy

ZUG, Switzerland, Aug. 22, 2018 /PRNewswire/ -- Drug developer Berlin Cures today announced the successful completion of its Phase 1 study of BC 007, a DNA-based aptamer compound that binds to and eliminates functional pathogenic autoantibodies for the treatment of cardiomyopathy. "The safety profile of BC 007 continues to be excellent," said Dr. Johannes Müller, founder and president of the Bo...
Read More

NEWS: Berlin Cures Announces Formation of Scientific Advisory Board

Berlin Cures Announces Formation of Scientific Advisory Board Inaugural Members Include Leading Experts in Cardiology and Autoimmunity ZUG, Switzerland, May 23, 2018 /PRNewswire/ -- Drug developer Berlin Cures today announced the formation of a Scientific Advisory Board (SAB) and the appointment of its first two members, Prof. Beda M. Stadler and Prof. Wilhelm Vetter, to help advance the cli...
Read More

NEWS: Phase-1 clinical study 

Berlin Cures Holding AG announces start of phase-1 study of BC007 ZURICH (Switzerland), November 14, 2016 --  Berlin Cures Holding AG announces the start of the clinical Phase-1-first-in-human-study of its drug candidate BC007. The study is a 2-part design with part 1 being a randomized, double-blinded, ascending single-dose study in healthy subjects, followed by part 2, which is an open, ascen...
Read More
Top